Lantheus Inks Isotope Deal with JHS as Ben Venue Exits the Picture

Matthew Skoufalos | | Radiology Business | Business Intelligence
As Ben Venue Laboratories continues to withdraw from the contract manufacturing services market, its client, Lantheus Medical Imaging, has found a new partner for the manufacture of a pair of contrast agents.Jubilant HollisterSteir brokered a five-year-deal with Lantheus to make Cardiolite and Neurolite, two technetium-based isotopes used in SPECT imaging. The arrangement carries the option of a five-year renewal after its expiry. The two companies have a similar deal in place for the manufacture of the ultrasound agent, Definity Vial. Lantheus is already looking to find additional partners with which to manufacture Cardiolite, Neurolite, and Definity by end-2013.

Matthew Skoufalos

Related Content

Mexico, not China, is biggest tariff concern among radiology vendors
DirectMed Imaging acquires Richardson Healthcare
Medical imaging trends to watch in 2025
Concerns about private equity's growing influence in radiology
Orano Med breaks ground on $265M thorium production site
Image-interpretation market scoreboard: Radiologists 72%, others 28%

Around the web

Health Imaging
American College of Radiology announces significant expansion of Lung Cancer Screening Registry

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

Health Imaging
AI reduces CT lung cancer screening workload by nearly 80%

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.